NCT03349021 is a NA clinical trial of Bougiecap in Esophagostenosis, sponsored by University of Ulm.

Who is sponsoring NCT03349021?

NCT03349021 is sponsored by University of Ulm.

What drugs are being tested in NCT03349021?

Interventions in NCT03349021: Bougiecap.

What condition does NCT03349021 study?

NCT03349021 studies Esophagostenosis.

Is NCT03349021 still recruiting?

NCT03349021 is currently completed. Last updated 17 October 2018.

Last reviewed 2018-10-17 · How we verify

NCT03349021

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bougiecap for Treatment of Benign Stenosis in GI Tract

Completed NA Last updated 17 October 2018

What this trial tests

NA trial testing Bougiecap in Esophagostenosis in 50 participants. Completed in 1 September 2018.

Timeline

1 February 2018

Primary endpoint
1 July 2018

1 September 2018

Quick facts

Lead sponsor	University of Ulm
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 February 2018
Primary completion	1 July 2018
Estimated completion	1 September 2018
Sites	3 locations across United Kingdom, Germany

Drugs / interventions tested

Bougiecap

Conditions studied

Esophagostenosis — all drugs for Esophagostenosis →

Sponsor

University of Ulm

Who can join

18 and older, any sex, with Esophagostenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Feasibility testing of a cap-assisted endoscopic bougienage for benign upper GI stenosis with direct optical control.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of Ulm trials

Trials by the same sponsor.

NCT07436195 — Imprinting in Metabolic Diseases - Identifying Epigenetic Mechanisms in Human Gestational Diabetes Through Cell-free DNA · recruiting
NCT07154524 — Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · recruiting
NCT06877143 — Hypercaloric PEG Nutrition in ALS to Sustain Energy Homeostasis · NA · recruiting
NCT06280079 — Ultra-high-caloric, Fatty Diet in ALS · NA · recruiting
NCT06627348 — Hilotherapy for Prevention of Chemotherapy-induced Peripheral Polyneuropathy · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03349021 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Ulm
Last refreshed: 17 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03349021.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing